Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD)

NCT06954805 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma
Lymphoma, B-Cell

Interventions

DRUG: Rituximab
DRUG: Etoposide
DRUG: Prednisone
DRUG: Vincristine
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DEVICE: CAPP-seq

Sponsor

Jennifer Amengual

Collaborators

[object Object]